olaparib,abiraterone
astrazeneca,merck
['crpc', 'propel', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
gutted to miss #gu23 this year but pleased to see the high number and quality of work presented. this updated analysis on propel strengthens the argument to use parpi+arsi in mcrpc in hrrm patients! 
CRUK Clinical Research Fellow in Med Oncology and Early Phase trials @UCLcancer and @UCLH. Alma mater @Cambridge_Uni. Interested in GU, Lung, Ovarian Ca.